When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Chronic myeloid leukemia

Última revisão: 24 Mar 2025
Última atualização: 29 Nov 2024

Resumo

Definição

História e exame físico

Principais fatores diagnósticos

  • splenomegaly
  • shortness of breath
  • left upper quadrant discomfort or fullness
  • epistaxis
  • arthralgia
  • sternal tenderness
Detalhes completos

Outros fatores diagnósticos

  • weight loss
  • excessive sweating
  • fever
  • pallor
  • bruising
  • retinal hemorrhages
Detalhes completos

Fatores de risco

  • age 65 to 74 years
  • ionizing radiation exposure
  • male sex
Detalhes completos

Investigações diagnósticas

Primeiras investigações a serem solicitadas

  • CBC
  • complete metabolic profile
  • peripheral blood smear
  • bone marrow aspirate and biopsy for cytogenetic analysis
  • quantitative reverse transcription PCR (qRT-PCR) including breakpoint analysis
  • fluorescence in situ hybridization (FISH)
Detalhes completos

Investigações a serem consideradas

  • mutational analysis
Detalhes completos

Algoritmo de tratamento

AGUDA

chronic phase

accelerated phase

Colaboradores

Autores

Michael J. Mauro, MD

Leader, Myeloproliferative Neoplasms Program, Leukemia Service

Attending Physician and Member

Memorial Sloan Kettering Cancer Center

Professor, Weill Cornell Medicine

New York

NY

Declarações

MJM has received institutional research support for clinical trials from Novartis, Bristol Myers Squibb, Takeda, and Sun Pharma/Sparc, and honoraria for consulting/advisory boards from Novartis, Bristol Myers Squibb, Takeda, and Pfizer.

Agradecimentos

Dr Michael Mauro would like to gratefully acknowledge Dr Tim Somervaille, Dr Han Myint, and Dr Robert Chen, the previous contributors to this topic.

Declarações

TS has received travel support and speaker expenses from Novartis, and has served as a consultant to Novartis for development of drugs for indications other than CML. HM sits on the advisory board of Novartis and Bristol Myers Squibb, and also does speaking engagements on their behalf. RC declares that he has no competing interests.

Revisores

Rebecca Connor, MD

Chief Fellow

Section of Hematology and Oncology

Department of Internal Medicine

Wake Forest University Baptist Medical Center

Winston-Salem

NC

Declarações

RC declares that she has no competing interests.

Richard E. Clark, MA, MD, FRCP, FRCPath

Professor of Haematology

Royal Liverpool University Hospital

Liverpool

UK

Declarações

None disclosed.

  • Diagnósticos diferenciais

    • Leukemoid reaction
    • Benign neutrophilic leukocytosis
    • Atypical CML
    Mais Diagnósticos diferenciais
  • Diretrizes

    • NCCN clinical practice guidelines in oncology: chronic myeloid leukemia
    • NCCN clinical practice guidelines in oncology: hematopoietic cell transplantation (HCT)
    Mais Diretrizes
  • Calculadoras

    EUTOS long-term survival (ELTS) score

    Sokal score for chronic myeloid leukemia

    Mais Calculadoras
  • padlock-lockedConectar-se ou assinar para acessar todo o BMJ Best Practice

O uso deste conteúdo está sujeito ao nosso aviso legal